Public Sector Pension Investment Board (PSP Investments)’s Sana Biotechnology SANA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-1,635,514
Closed -$6.33M 1318
2023
Q3
$6.33M Sell
1,635,514
-3,735,779
-70% -$20.1M 0.05% 273
2023
Q2
$32M Sell
5,371,293
-1,028,707
-16% -$5.93M 0.22% 81
2023
Q1
$20.9M Hold
6,400,000
0.15% 117
2022
Q4
$25.3M Hold
6,400,000
0.19% 93
2022
Q3
$38.4M Hold
6,400,000
0.32% 64
2022
Q2
$41.2M Buy
6,400,000
+2,268,751
+55% +$14.5M 0.35% 65
2022
Q1
$34.1M Hold
4,131,249
0.21% 95
2021
Q4
$64M Hold
4,131,249
0.34% 57
2021
Q3
$93M Sell
4,131,249
-376,862
-8% -$7.91M 0.53% 32
2021
Q2
$88.6M Buy
4,508,111
+376,862
+9% +$8.54M 0.53% 36
2021
Q1
$138M Buy
+4,131,249
New +$135M 0.89% 14

Other funds holding SANA

Public Sector Pension Investment Board (PSP Investments)'s SANA Position: Q4 2023 in Review

Public Sector Pension Investment Board (PSP Investments) sold out of Sana Biotechnology (SANA) in Q4 2023, closing a stake of 1,635,514 shares — an estimated $6.33M sold.

Public Sector Pension Investment Board (PSP Investments) first reported a position in SANA in Q1 2021 and held it in 11 quarters. The position peaked at $138M in Q1 2021. 132 funds tracked by Wall St. Rank hold SANA as of Q4 2023.

  • Public Sector Pension Investment Board (PSP Investments) reported no remaining Sana Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Public Sector Pension Investment Board (PSP Investments) sold 1,635,514 Sana Biotechnology shares in Q4 2023, an estimated $6.33M.
  • Public Sector Pension Investment Board (PSP Investments) first reported a position in Sana Biotechnology in Q1 2021 and held it in 11 quarters.
  • Public Sector Pension Investment Board (PSP Investments)'s Sana Biotechnology position peaked at $138M in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2023.

Based on Public Sector Pension Investment Board (PSP Investments)'s 13F filing for Q4 2023, filed 14 Feb 2024.